Kura Oncology Inc Stock Price, News & Analysis

Kura Oncology announced new preclinical findings for KO-539, a selective menin inhibitor, at the ASH Annual Meeting in Atlanta. These data demonstrate KO-539's ability to induce growth inhibition and differentiation in AML cells with KMT2A rearrangements or NPM1 mutations. The combination of KO-539 with the standard of care, venetoclax, shows synergistic effects, enhancing survival in aggressive AML models. KO-539 is currently in a Phase 1b clinical trial for relapsed/refractory AML, with an Orphan Drug Designation from the FDA.

Kura Oncology announced a partial clinical hold on its KOMET-001 Phase 1b study of KO-539 for relapsed or refractory acute myeloid leukemia (AML) due to a Grade 5 serious adverse event (a patient death) linked to differentiation syndrome. Current patients may continue treatment, but new enrollments are halted. Kura is collaborating with the FDA to lift the hold. As a result, the company has suspended guidance on enrollment completion and the recommended Phase 2 dose of KO-539 until clarity is achieved regarding the hold.

Kura Oncology announced that its CEO, Troy Wilson, will participate in two virtual investor conferences. The first is a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 11:20 a.m. ET. The second is at the JMP Securities Hematology and Oncology Summit on December 7, 2021, at 2:20 p.m. ET. Audio webcasts of both events will be available on Kura's website, with archived replays accessible afterward. Kura is focused on developing precision medicines for cancer treatment, with ongoing trials for promising drug candidates.

Kura Oncology reported its Q3 2021 financial results with a net loss of $33.4 million, compared to $23.8 million in Q3 2020. The company continues to enroll patients in its Phase 1b study of KO-539 for AML, with plans for a comprehensive development strategy. Kura activated the first site for the Phase 1/2 trial of tipifarnib plus alpelisib in HNSCC. As of September 30, 2021, Kura holds $543.4 million in cash, providing a runway into 2024. The upcoming ASH presentation will discuss the potential of KO-539 in combination with venetoclax.

Kura Oncology, Inc. (Nasdaq: KURA) announced its participation in the Credit Suisse 30th Annual Healthcare Conference. The event features a virtual fireside chat with CEO Troy Wilson on November 9, 2021, at 3:30 p.m. ET. Investors can access a live audio webcast on Kura's website, with a replay available afterward. Kura specializes in precision medicines for cancer, focusing on small molecule drug candidates. Key programs include KO-539 for relapsed/refractory AML and Tipifarnib for HRAS mutant head and neck cancer, highlighting the company's innovative approach to oncology.

Kura Oncology, Inc. (Nasdaq: KURA) will release its third quarter 2021 financial results on November 4, 2021, after U.S. markets close. A webcast and conference call, scheduled for 4:30 p.m. ET / 1:30 p.m. PT, will provide financial insights and a corporate update. The call can be accessed by domestic and international callers with specific dial-in information. Kura focuses on innovative cancer treatments, including KO-539 for AML and Tipifarnib for HRAS mutant HNSCC, highlighting its commitment to precision medicine.

Kura Oncology (Nasdaq: KURA) has appointed Teresa Bair as Chief Legal Officer and Corporate Secretary. Bair brings over 25 years of legal experience, recently serving as General Counsel at Athenex, where she assisted in multiple NDA filings and an FDA approval. Kura's President, Troy Wilson, emphasized her expertise in drug development, crucial for advancing their oncology drug pipeline. Kura focuses on precision medicines for cancer, with pipeline candidates like KO-539 and tipifarnib, which has gained Breakthrough Therapy Designation.

Kura Oncology (Nasdaq: KURA) announced that Troy Wilson, Ph.D., J.D., CEO, will participate in two virtual investor conferences. He will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with an on-demand recording available starting at 7:00 a.m. ET. Additionally, he will engage in a fireside chat at the Cantor Global Healthcare Conference on September 27, 2021, at 3:20 p.m. ET. Audio webcasts of both events will be accessible on Kura's website, with archived replays available after both events.

Kura Oncology reported its Q2 2021 results, highlighting key advancements in clinical trials and collaborations. The first patients have been dosed in the Phase 1b cohorts for KO-539, a menin inhibitor targeting relapsed/refractory AML. A collaboration with Novartis aims to assess tipifarnib with alpelisib in HNSCC. Kura has also nominated KO-2806 as its lead candidate in a new farnesyl transferase program. Financially, the company reported a net loss of $33.7 million with $567.5 million in cash reserves expected to sustain operations into 2024.